SEARCH:   Advanced

Blood, 1 April 2006, Vol. 107, No. 7, pp. 2786-2789. Prepublished online as a Blood First Edition Paper on December 15, 2005; DOI 10.1182/blood-2004-01-0113. This Article Full Text Full Text (PDF) Supplemental Tables All Versions of this Article: 2004-01-0113v1 107/7/2786    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by von Bergwelt-Baildon, M. Articles by Schultze, J. L. Search for Related Content PubMed PubMed Citation Articles by von Bergwelt-Baildon, M. Articles by Schultze, J. L. Related Collections Cell Adhesion and Motility Immunotherapy Immunobiology Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  IMMUNOBIOLOGY CD40-activated B cells express full lymph node homing triad and induce T-cell chemotaxis: potential as cellular adjuvants Michael von Bergwelt-Baildon, Alexander Shimabukuro-Vornhagen, Alexey Popov, Nela Klein-Gonzalez, Francesca Fiore, Svenja Debey, Andreas Draube, Britta Maecker, Isaura Menezes, Lee M. Nadler, and Joachim L. Schultze From the Molecular Tumor Biology and Tumor Immunology, Clinic I of Internal Medicine, Hematology & Oncology, and the Center for Molecular Medicine, University of Cologne, Cologne, Germany; Divisione di Ematologia dell'Universita' di Torino and Laboratorio di Ematologia Oncologica, Centro di Ricerca in Medicina Sperimentale (CeRMS), Ospedale San Giovanni Battista, Torino, Italy; Pediatric Hematology/Oncology, Medical School of Hannover, Hannover, Germany; the Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; and Harvard Medical School, Boston, MA. CD40-activated B cells (CD40-B cells) have previously been introduced as an alternative source of antigen-presenting cells for immunotherapy. CD40-B cells can prime naive and expand memory T cells, and they can be generated in large numbers from very small amounts of peripheral blood derived from healthy individuals or cancer patients alike. Administration of CD40-B cells as a cellular adjuvant would require these cells to migrate toward secondary lymphoid organs and attract T cells in situ, processes guided by specific chemokines and chemokine receptors. Here, we demonstrate that primary, human CD40-B cells express a pattern of adhesion molecules and chemokine receptors necessary for homing to secondary lymphoid organs and have the capacity to migrate to cognate ligands. Furthermore, we show that CD40-B cells express important T-cell attractants and induce strong T-cell chemotaxis. These findings further support the use of CD40-B cells as cellular adjuvant for cancer immunotherapy. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

	Blood Online is supported in part by Genentech BioOncology and Biogen Idec
	Copyright © 2006 by American Society of Hematology         Online ISSN: 1528-0020